Comment from International Pemphigus and Pemphigoid Foundation

Summary: The International Pemphigus and Pemphigoid Foundation (IPPF) supports the FDA's initiative on drug repurposing, specifically advocating for a more proactive approach to update labels for existing medications used in treating rare autoimmune blistering diseases. They argue that the FDA should collaborate with the NIH and CMS to bridge the gap between clinical evidence and regulatory labeling, especially where commercial incentives for off-patent drugs are weak.